Vijay Pandey

Dr. Vijay Pandey

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 February 2024 in Cancer Research
Verified
Journal Article
Closed access
PDF file
LYLinlin Yan
Linlin Yan
MWMingming Wu
Mingming Wu
TWTianyu Wang
Tianyu Wang
HYHui Yuan
Hui Yuan
XZXiao Zhang
Xiao Zhang
TZTao Zhu
Tao Zhu
Reprogramming of energy metabolism exerts pivotal functions in cancer progression and immune surveillance. Identification of the mechanisms mediating metabolic changes in cancer may lead to improved strategies to suppress tumor growth and stimulate antitumor immunity. Here, it was observed that the secretomes of hypoxic breast cancer cells and breast cancer stem cells (BCSC) induced reprogramming of metabolic pathways, particularly glycolysis, in normoxic breast cancer cells. Screening of the BCSC secretome identified MIF as a pivotal factor potentiating glycolysis. Mechanistically, MIF increased c-MYC–mediated transcriptional upregulation of the glycolytic enzyme aldolase C by activating WNT/β-catenin signaling. Targeting MIF attenuated glycolysis and impaired xenograft growth and metastasis. MIF depletion in breast cancer cells also augmented intratumoral cytolytic CD8+ T cells and proinflammatory macrophages while decreasing regulatory T cells and tumor-associated neutrophils in the tumor microenvironment. Consequently, targeting MIF improved the therapeutic efficacy of immune checkpoint blockade in triple-negative breast cancer. Collectively, this study proposes MIF as an attractive therapeutic target to circumvent metabolic reprogramming and immunosuppression in breast cancer. Significance: MIF secreted by breast cancer stem cells induces metabolic reprogramming in bulk tumor cells and engenders an immunosuppressive microenvironment, identifying MIF targeting as a strategy to improve immunotherapy efficacy in breast cancer.

27 July 2022 in Frontiers in Oncology
Verified
Journal Article
Open access
VBVipul Bhardwaj
Vipul Bhardwaj
ASArundhiti Sharma
Arundhiti Sharma
SPSnijesh Valiya Parambath
Snijesh Valiya Parambath
IGIjaz Gul
Ijaz Gul
XZXi Zhang
Xi Zhang
VPVijay Pandey
Vijay Pandey
Endometrial cancer (EC) is a prevalent uterine cancer that remains a major contributor to cancer-associated morbidity and mortality. EC diagnosed at advanced stages shows a poor therapeutic response. The clinically utilized EC diagnostic approaches are costly, time-consuming, and are not readily available to all patients. The rapid growth in computational biology has enticed substantial research attention from both data scientists and oncologists, leading to the development of rapid and cost-effective computer-aided cancer surveillance systems. Machine learning (ML), a subcategory of artificial intelligence, provides opportunities for drug discovery, early cancer diagnosis, effective treatment, and choice of treatment modalities. The application of ML approaches in EC diagnosis, therapies, and prognosis may be particularly relevant. Considering the significance of customized treatment and the growing trend of using ML approaches in cancer prediction and monitoring, a critical survey of ML utility in EC may provide impetus research in EC and assist oncologists, molecular biologists, biomedical engineers, and bioinformaticians to further collaborative research in EC. In this review, an overview of EC along with risk factors and diagnostic methods is discussed, followed by a comprehensive analysis of the potential ML modalities for prevention, screening, detection, and prognosis of EC patients.

21 June 2020 in Cells
Verified
Journal Article
Open access
PDF file
Samarth KansaraSamarth Kansara
Samarth Kansara
VPVijay Pandey
Vijay Pandey
PEPeter E.Lobie
Peter E.Lobie
Gautam SethiGautam Sethi
Gautam Sethi
MGManoj Garg
Manoj Garg
APAmit Kumar Pandey
Amit Kumar Pandey
Triple-negative breast cancer (TNBC) is one of the most lethal forms of breast cancer (BC), with a significant disease burden worldwide. Chemoresistance and lack of targeted therapeutics are major hindrances to effective treatments in the clinic and are crucial causes of a worse prognosis and high rate of relapse/recurrence in patients diagnosed with TNBC. In the last decade, long non-coding RNAs (lncRNAs) have been found to perform a pivotal role in most cellular functions. The aberrant functional expression of lncRNAs plays an ever-increasing role in the progression of diverse malignancies, including TNBC. Therefore, lncRNAs have been recently studied as predictors and modifiers of chemoresistance. Our review discusses the potential involvement of lncRNAs in drug-resistant mechanisms commonly found in TNBC and highlights various therapeutic strategies to target lncRNAs in this malignancy.

9 July 2025 in Medcomm
Verified
Journal Article
Open access
TWTesfaye Wolde
Tesfaye Wolde
VBVIPUL BHARDWAJ
VIPUL BHARDWAJ
VPVijay Pandey
Vijay Pandey
Integrating bioinformatics tools has profoundly transformed precision oncology by identifying essential molecular targets for personalized treatment. The rapid development of high‐throughput sequencing and multiomics technologies creates complex datasets that require robust computational methods to extract meaningful insights. Nonetheless, the clinical application of multiomics data continues to pose significant challenges. This review explores advanced bioinformatics tools utilized within multiomics, emphasizing their pivotal role in discovering cancer biomarkers. Cloud‐based platforms, such as Galaxy and DNAnexus, facilitate streamlined data processing, while single‐cell analysis software, including Seurat, identifies rare cellular subpopulations. Further integration of artificial intelligence with machine learning approaches improves predictive modeling and diagnostic accuracy. Spatial omics technologies correlate molecular signatures within tumor microenvironments, guiding treatment strategies. Bioinformatics integrates these technologies to establish a new standard in precision oncology, thereby enhancing therapy efficacy. Collaborative initiatives between The Cancer Genome Atlas and cBioPortal expedite advancements through the sharing open data and implementing standardized methodologies. Advancing multiomics integration techniques alongside improved computational capabilities is essential for discovering new biomarkers and refining precision medicine strategies. Future efforts should focus on merging multiomics techniques with innovative computational methods to drive novel biomarker discovery and improve precision medicine applications.

1 August 2021 in Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
Verified
Journal Article
Closed access
Yan Qin TanYan Qin Tan
Yan Qin Tan
XZXi Zhang
Xi Zhang
SZShuwei Zhang
Shuwei Zhang
TZTao Zhu
Tao Zhu
MGManoj Garg
Manoj Garg
VPVijay Pandey
Vijay Pandey

1 April 2021 in Cancer Letters
Verified
Journal Article
Closed access
VBVipul Bhardwaj
Vipul Bhardwaj
Yan Qin TanYan Qin Tan
Yan Qin Tan
MWMing Ming Wu
Ming Ming Wu
LMLan Ma
Lan Ma
TZTao Zhu
Tao Zhu
VPVijay Pandey
Vijay Pandey